Why the study?
Does the development of hypertension predict improved survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy?
Population
101 consecutive patients with metastatic colorectal cancer treated with standard chemotherapy combined with…
Comparison
Development of ≥grade 1 hypertension during… vs Remaining normotensive during…
Design
Cohort
Follow-up
median 64 months (for patients alive)
Authors
Loading...
Hypertension may indicate better prognosis with bevacizumab in metastatic colorectal cancer; hypothesis-generating and should not yet change practice.
Does the development of hypertension predict improved survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy?
The development of hypertension during bevacizumab treatment may serve as a prognostic biomarker for improved survival in patients with metastatic colorectal cancer.
Österlund et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: